Welcome to our dedicated page for Pennant Group SEC filings (Ticker: PNTG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pennant Group, Inc. filings document the public reporting of a healthcare services holding company with operating subsidiaries in home health, hospice, home care and senior living. Recent Form 8-K reports furnish quarterly and annual results, Regulation FD investor materials, material agreements and amendments tied to acquisitions and financing arrangements.
Proxy filings cover governance, board matters, executive compensation and shareholder voting items. Other material-event amendments provide acquisition-related financial statements and pro forma information, while credit agreement disclosures describe term loans, leverage and coverage covenants, restrictions on indebtedness, liens, dispositions and restricted payments, and healthcare-law-related default provisions.
Pennant Group, Inc. executive Kirk Sterling Cheney, EVP, General Counsel and Corporate Secretary, reported a sale of 1,393 shares of common stock on August 6, 2026. The shares were sold at a price of $38.522 per share. Following this transaction, Cheney directly holds 18,401 shares of Pennant Group common stock. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on August 26, 2022, indicating it was executed under a pre-arranged trading program.
Pennant Group, Inc. reported that Chief Executive Officer Brent Guerisoli sold 4,285 shares of common stock on 2026-08-06 at an average price of $38.522 per share in an open-market or private transaction. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on May 31, 2024, and left him holding 99,544 shares directly.
Pennant Group, Inc. Chief Clinical Officer Jason Paul Steik reported a sale of 1,394 shares of common stock on 2026-08-06 at $38.522 per share in an open-market or private transaction. Following this transaction, he directly holds 15,106 shares of Pennant Group common stock. The trade was affirmed as made under a Rule 10b5-1 trading plan.
Pennant Group insider Brent J. Guerisoli has filed to sell 4,285 shares of common stock through Fidelity Brokerage Services on 08/06/2026. These shares were acquired as restricted stock vesting on 07/27/2026 as compensation. The filing also lists sales in the prior three months totaling 4,508, 3,165, and 3,159 shares for aggregate amounts of $158,139.96, $128,214.15, and $131,303.84, respectively.
The Pennant Group, Inc. reported higher Q2 2026 results, with revenue of 297,984 (in thousands) versus 219,501 (in thousands) a year earlier and income from operations of 17,186 (in thousands). Net income attributable to Pennant was 9,082 (in thousands), or diluted EPS of $0.25.
For the first six months, revenue was 583,348 (in thousands) and net income attributable to Pennant was 17,601 (in thousands). Medicare and Medicaid together represented 64.3% of Q2 revenue. Home health and hospice produced 237,353 (in thousands) of Q2 revenue, senior living 58,497 (in thousands), and Segment Adjusted EBITDAR from Operations totaled 56,913 (in thousands).
Total assets were 1,037,291 (in thousands) at June 30, 2026, including a new equity method investment of 28,798 (in thousands). Long-term debt was 198,500 (in thousands) under an amended credit facility and term loans, with a weighted average interest rate of 5.88%. Operating cash flow for the first half was 18,425 (in thousands), while significant investing outflows reflected acquisitions and the equity method investment. The company also outlines new CMS hospice and home health reimbursement updates, a nationwide enrollment moratorium for new hospices and home health agencies, and expanded enrollment scrutiny as key regulatory developments.
The Pennant Group, Inc. reported strong second-quarter 2026 results, with total revenue of $298.0 million, up 35.8% year over year. Net income was $9.1 million, and GAAP diluted EPS was $0.25, while adjusted diluted EPS was $0.36.
Home health and hospice revenue rose to $237.8 million, up 43.2%, driven by total home health admissions of 28,947, up 62.3%, and hospice average daily census of 5,477, up 40.1%. Senior living revenue increased to $60.2 million, up 12.6%, supported by slightly higher occupancy and higher average monthly revenue per occupied unit.
Consolidated Adjusted EBITDA reached $24.3 million, up 48.2%, and Consolidated Adjusted EBITDAR was $37.6 million, up 33.3%. Management raised full-year 2026 guidance to revenue of $1,171.1–$1,190.1 million, adjusted diluted EPS of $1.34–$1.41, and adjusted EBITDA of $94.4–$98.0 million, including contributions from recently acquired UnitedHealth and Amedisys assets.
Vanguard Capital Management LLC filed a Schedule 13G reporting passive ownership of common stock of Pennant Group Inc/The. Vanguard and certain affiliated entities report beneficial ownership of 1,742,207 shares of Pennant Group common stock, representing 5.01% of the class as of June 30, 2026.
The filing states Vanguard has sole voting power over 261,326 shares and sole dispositive power over 1,742,207 shares, with no shared voting or dispositive power. The position includes securities held by Vanguard funds and managed accounts for which Vanguard or specified affiliates exercise voting and/or dispositive authority. Vanguard notes that various investment companies and other managed accounts have the right to receive dividends and sale proceeds, but no other individual person has an interest in more than 5% of the class.
SMITH BARRY M reported acquisition or exercise transactions in this Form 4 filing.
Pennant Group, Inc. director Barry M. Smith received a grant of 1,900 shares of Common Stock on July 15, 2026 at a reported price of $0.0000 per share. These shares vest in three annual installments beginning July 15, 2027. Following this award, he directly holds 102,499 shares of Pennant Group stock.